GNQ Unveils AI-Powered Platform Prototype Delivering 128% AUC Improvement in Personalized Clomiphene Dosing Optimization
GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, announced the successful development and validation of its AI-powered Drug Assessment Platform prototype for clomiphene citrate dose optimization. The fertility treatment market represents a significant opportunity, with clomiphene citrate being a first-line therapy for ovulatory dysfunction affecting millions of women globally. This proof-of-concept demonstrates […]
